November 2nd 2022
Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
October 26th 2022
Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
October 5th 2022
Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.
Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.
September 28th 2022
Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.
Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.
September 21st 2022
Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.
Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.
October 1st 2021
Takeaways from a discussion on treatment advances in hepatocellular carcinoma.
Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.
September 24th 2021
An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.
Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.
September 17th 2021
A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.
Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.
September 10th 2021
An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.
Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.
September 3rd 2021
Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.
Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.
August 27th 2021
Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.
Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.